Sahajanand Medical Technologies’ ₹475.48 crore IPO saw a subscription of 0.40 times as of 10:20 AM on October 16, 2026, the second day of bidding. The issue is priced at ₹327 to ₹344 per share and will close on October 19, 2026.
The basis of allotment is expected to be finalised on October 21, with the company’s shares tentatively scheduled to list on the BSE and NSE on October 23, 2026.
Sahajanand Medical Technologies IPO – Issue Details
- Issue Type: Book Built Issue (OFS only)
- Total Issue Size: Up to ₹475.48 crore
- Fresh Issue: Not Applicable
- Offer for Sale (OFS): Up to ₹475.48 crore
- Face Value: ₹1 per equity share
- Price Band: ₹327 to ₹344 per share
- Lot Size: 43 shares
- Minimum Investment Amount (Retail Investor): ₹14,792 (43 shares at the upper price)
- Listing: BSE, NSE
- Book Running Lead Managers: Motilal Oswal Investment Advisors Limited, Avendus Capital Private Limited, HSBC Securities and Capital Markets (India) Private Limited, Nuvama Wealth Management Limited
- Registrar: MUFG Intime India Private Limited
Sahajanand Medical Technologies IPO Timeline (Tentative)
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
15 October 2026 |
|
Subscription Closing Date |
19 October 2026 |
|
Basis of Allotment Date |
21 October 2026 |
|
Refund Initiation Date |
22 October 2026 |
|
Credit of Shares |
22 October 2026 |
|
Listing on BSE and NSE |
23 October 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
Sahajanand Medical Technologies IPO Day 2 Subscription Status
[October 16, 2026, 10:20 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.37x |
|
Non-Institutional Investors (NIIs) |
0.28x |
|
Retail Individual Investors (RIIs) |
0.48x |
|
Employees |
0.09x |
|
Total |
0.40x |
About Sahajanand Medical Technologies Limited
Founded in 2001, Sahajanand Medical Technologies develops and manufactures medical devices, with a focus on research and development. Its product range caters to vascular and structural heart procedures and includes coronary stents and balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons (DCBs).
The company’s products were distributed across 77 countries in FY2026 and 65 countries, including India, during the three months ended June 30, 2026.
Key Financial Highlights
|
Particulars |
For the three month period ended June 30, 2026 (in ₹ crore) |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
|
Revenue from operations |
351.67 |
1,210.50 |
1,024.88 |
|
EBITDA |
48.58 |
170.65 |
128.02 |
|
Profit After Tax (PAT) |
15.09 |
69.08 |
25.15 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here
Leave a Reply